Post Transplant Study

This study has been completed.
Information provided by:
Amgen Identifier:
First received: November 2, 2006
Last updated: December 20, 2007
Last verified: December 2007

Retrospective chart review to gather information on Sensipar patterns of use and effects on biochemical parameters in renal transplant recipients

Condition Intervention
Kidney Tansplant
Secondary Hyperparathyroidism
Drug: Sensipar after Post Transplant

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: A Retrospective Evaluation of Sensipar Use in Renal Transplant Recipients

Resource links provided by NLM:

Further study details as provided by Amgen:

Estimated Enrollment: 50
Study Start Date: August 2005

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both

Inclusion Criteria:

  • Adults >= 18 years old
  • Subjects who have received Sensipar for a duration of at least 3 months, beginning at least 3 months after a kidney transplant. Subjects must have begun Sensipar teatment no later than Februry 28, 2005 at treating physician's discretion.

Exclusion Criteria:

  • Subjects who received Sensipar before undergoing a kidney transplant
  • Subjects receiving dialysis post-transplant
  Contacts and Locations
Please refer to this study by its identifier: NCT00395902

Sponsors and Collaborators
Study Director: MD Amgen
  More Information

Additional Information:
No publications provided

Responsible Party: Global Development Leader, Amgen Inc. Identifier: NCT00395902     History of Changes
Other Study ID Numbers: 20040261, 2004261
Study First Received: November 2, 2006
Last Updated: December 20, 2007
Health Authority: United States: Institutional Review Board

Keywords provided by Amgen:

Additional relevant MeSH terms:
Hyperparathyroidism, Secondary
Parathyroid Diseases
Endocrine System Diseases processed this record on April 17, 2014